An effective vaccine for dengue fever, which infects as many as 400,000 people a year according to the World Health Organisation
(WHO), has eluded scientists for decades.
A vaccine to prevent dengue (Dengvaxia) is available in some countries for people ages 9-45 years old. But the WHO
recommends that the vaccine only be given to persons with confirmed prior dengue virus infection.
According to the US Centers for Disease Control and Prevention (CDC), the vaccine manufacturer, Sanofi Pasteur, announced in 2017 that 'people who
receive the vaccine and have not been previously infected with a dengue virus may be at risk of developing severe dengue if they get dengue after being vaccinated'.
A medic provides medicine as part of Covid-19 treatment at Sri H. N. Reliance Foundation Hospital in collaboration with the Brihanmumbai Municipal Corporation (BMC), in Mumbai. Photo: PTI
'There are some viruses that we still do not have vaccines against. We can't make an absolute assumption that a vaccine will appear at all, or if it does appear, whether it will pass all the tests of efficacy and safety,' Dr David Nabarro, professor of global health at Imperial College London, was quoted as saying in the report.
According to Dr Anthony Fauci, Director of the National
Institute of Allergy and Infectious Diseases (NIAID), the vaccine could happen in 12-18 months. However, 'we've never accelerated a vaccine in a year to 18 months,' Dr Peter Hotez, dean of the National
School of Tropical Medicine at Baylor College of Medicine in Houston, was quoted as saying.
The COVID-19 disease could be with us many years into the future and lockdown
are not sustainable economically.
'It means the culture of shrugging off a cough or light cold symptoms and trudging into work should be over. Experts also predict a permanent change in attitudes towards remote working,' said the report.
Currently, a vaccine candidate for COVID-19 was identified by researchers from the Oxford Vaccine Group and Oxford's Jenner Institute. The potential upcoming vaccine, ChAdOx1 nCoV-19, is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein.
According to the WHO, from a total of 102 candidate vaccines in the race, eight leading vaccines are in the human testing phase. What probably separates ChAdOx1 - known as recombinant viral vector vaccine - from the rest is the time it has promised to take in order to deliver mass quantities. However, no one is 100 per cent sure, yet.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.